Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness

Summary

The main focus of the study is to show that SmofKabiven® extra Nitrogen, in a realistic clinical setting, enables to meet high protein requirements in patients during the first week after onset of critical illness, without risk of overfeeding with energy.

Timeline

Start

2019-11-26

Primary completion

2020-03-24

Completion

2020-03-24

Outcome

Outcome not reported

Stopped: “Study had to be put on hold after the outbreak of Covid-19 in the participating countries and was terminated in September 2020 since a date for re-starting was not foreseeable.”

Drugs

Indications

No indication recorded.